The call is issued by the Federal Ministry of Education and Research (BMBF) to support innovative research projects applying Artificial Intelligence (AI) in drug discovery and development. This initiative is designed to accelerate the pharmaceutical research process by integrating advanced AI tools into the drug discovery pipeline, thereby addressing high medical needs and reducing the time and cost associated with bringing new medicines to market. The call aims at bridging the gap between existing AI technologies and their practical implementation in pharmaceutical R&D. By targeting projects that harness AI methods for drug candidate identification, repurposing of existing compounds, high-throughput screening, and clinical trial design, the funding is intended to foster interdisciplinary collaboration among academia, research institutes, and industry. Emphasis is placed on enhancing data availability, standardization, and quality to train AI systems effectively.

Traditional drug development is often characterized by lengthy timelines, high expenses, and significant risk. Recognizing these challenges, the initiative seeks to support projects that streamline research and development processes and increase the probability of successful outcomes. The funding measure is part of a broader government strategy aimed at positioning Germany as a leader in AI innovation and pharmaceutical research. By leveraging AI, the projects are expected to achieve measurable improvements in efficiency, cost reduction, and accelerated timelines from laboratory research to clinical application.

Applicants must demonstrate a comprehensive, interdisciplinary approach that combines robust expertise in both pharmaceutical sciences and artificial intelligence. Collaborative efforts are highly encouraged, particularly those that involve multiple stakeholders such as universities, research organizations, and industry partners. Eligible projects may range from preclinical studies to early-stage clinical trials (up to Phase IIa) but must clearly articulate their practical relevance to human medicine. The initiative excludes projects focused exclusively on the development of new AI methodologies without a direct application in drug research.

The call also outlines detailed requirements regarding project planning, milestones, and adherence to regulatory standards, ensuring that successful proposals not only innovate but also comply with all applicable scientific and legal guidelines. Furthermore, the funding supports activities aimed at enhancing data management and scientific communication to facilitate widespread dissemination of research outcomes.

Overall, this call provides a unique opportunity for pioneering projects that seek to revolutionize drug research through the application of AI, ultimately contributing to improved healthcare outcomes. Applicants are encouraged to submit comprehensive proposals that clearly define their methodology, anticipated impact, and plans for long-term sustainability. Results must be transformative.

Find here the original call in german: Funding for AI Applications in Drug Research

Opening: 19-02-2025
Deadline first application stage: 30-04-2025